MX9704372A - Tratamiento de carcinoma. - Google Patents
Tratamiento de carcinoma.Info
- Publication number
- MX9704372A MX9704372A MX9704372A MX9704372A MX9704372A MX 9704372 A MX9704372 A MX 9704372A MX 9704372 A MX9704372 A MX 9704372A MX 9704372 A MX9704372 A MX 9704372A MX 9704372 A MX9704372 A MX 9704372A
- Authority
- MX
- Mexico
- Prior art keywords
- carcinoma treatment
- treatment
- carcinoma
- carcinomas
- inducer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Para el tratamiento de carcinomas en células epiteliales y para la prevencion de proliferacion de células epiteliales se usa un enlazador de receptor de CD40; el CD40 se puede usar junto con por lo menos un agente antineoplásico y/o inductor de CD40.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9425060.2A GB9425060D0 (en) | 1994-12-13 | 1994-12-13 | Carcinoma treatment |
PCT/GB1995/002807 WO1996018413A1 (en) | 1994-12-13 | 1995-12-01 | Carcinoma treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9704372A true MX9704372A (es) | 1998-02-28 |
Family
ID=10765814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9704372A MX9704372A (es) | 1994-12-13 | 1995-12-01 | Tratamiento de carcinoma. |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0806963B1 (es) |
JP (1) | JP4076230B2 (es) |
AT (1) | ATE203676T1 (es) |
AU (1) | AU691996B2 (es) |
CA (1) | CA2207779C (es) |
DE (1) | DE69522012T2 (es) |
FI (1) | FI118918B (es) |
GB (1) | GB9425060D0 (es) |
MX (1) | MX9704372A (es) |
NO (1) | NO318587B1 (es) |
NZ (1) | NZ296161A (es) |
WO (1) | WO1996018413A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ278740A (en) * | 1993-12-23 | 1998-05-27 | Immunex Corp | Treating disease characterised by neoplastic cells expressing cd40 using a cd40 binding protein |
US7070771B1 (en) | 1996-12-09 | 2006-07-04 | Regents Of The University Of California | Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells |
HU228180B1 (hu) * | 1998-08-11 | 2013-01-28 | Biogen Idec Inc | Anti-CD20-ellenanyag alkalmazása B-sejtes limfómák kombinációs terápiájára |
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
US7138379B2 (en) * | 2000-07-26 | 2006-11-21 | Schering Aktiengesellschaft | Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons |
GB0025132D0 (en) * | 2000-10-13 | 2000-11-29 | Medical Res Council | Method |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
US7786282B2 (en) | 2001-12-06 | 2010-08-31 | The Regents Of The University Of California | Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain |
US7495090B2 (en) | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
PT1680141E (pt) * | 2003-11-04 | 2010-12-20 | Novartis Vaccines & Diagnostic | Métodos terapêuticos para tumores sólidos que expressam o antigénio de superfície celular cd40 |
US20050136055A1 (en) | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
ES2354865T3 (es) | 2005-05-26 | 2011-03-18 | Seattle Genetics, Inc. | Anticuerpos anti-cd40 humanizados y métodos para utilizarlos. |
WO2007053767A1 (en) | 2005-11-01 | 2007-05-10 | Novartis Ag | Uses of anti-cd40 antibodies |
US9005974B2 (en) | 2005-12-09 | 2015-04-14 | Academish Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
JP5753339B2 (ja) | 2005-12-09 | 2015-07-22 | アカデミッシュ メディッシュ セントラム ビーアイジェイ ド ユニバーシテイト バン アムステルダム | 抗体産生細胞の安定性に影響を与える手段および方法 |
NZ571757A (en) | 2006-04-21 | 2012-01-12 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer |
CA2704499C (en) | 2007-11-07 | 2020-03-10 | Genentech, Inc. | Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies |
BRPI1011394A8 (pt) | 2009-04-18 | 2018-06-26 | Genentech Inc | método para avaliação de responsividade de linforma de células b ao tratamento com anticorpos anti-cd40 |
DK2454283T3 (en) | 2009-07-15 | 2018-05-07 | Aimm Therapeutics Bv | METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES |
AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
PT2646466T (pt) | 2010-12-02 | 2017-06-07 | Aimm Therapeutics Bv | Meios e métodos para produzir anticorpos de alta afinidade |
SG194701A1 (en) | 2011-04-29 | 2013-12-30 | Apexigen Inc | Anti-cd40 antibodies and methods of use |
ES2879552T3 (es) | 2012-10-30 | 2021-11-22 | Apexigen Inc | Anticuerpos anti-CD40 y métodos de uso |
JP6747975B2 (ja) | 2014-01-31 | 2020-08-26 | アイム・セラピューティクス・べー・フェー | 安定な抗体を産生するための手段及び方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
-
1994
- 1994-12-13 GB GBGB9425060.2A patent/GB9425060D0/en active Pending
-
1995
- 1995-12-01 CA CA002207779A patent/CA2207779C/en not_active Expired - Fee Related
- 1995-12-01 AU AU39884/95A patent/AU691996B2/en not_active Ceased
- 1995-12-01 MX MX9704372A patent/MX9704372A/es not_active IP Right Cessation
- 1995-12-01 EP EP95938518A patent/EP0806963B1/en not_active Expired - Lifetime
- 1995-12-01 JP JP51844696A patent/JP4076230B2/ja not_active Expired - Fee Related
- 1995-12-01 NZ NZ296161A patent/NZ296161A/en not_active IP Right Cessation
- 1995-12-01 WO PCT/GB1995/002807 patent/WO1996018413A1/en active IP Right Grant
- 1995-12-01 AT AT95938518T patent/ATE203676T1/de active
- 1995-12-01 DE DE69522012T patent/DE69522012T2/de not_active Expired - Lifetime
-
1997
- 1997-06-12 FI FI972484A patent/FI118918B/fi active IP Right Grant
- 1997-06-13 NO NO19972732A patent/NO318587B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU691996B2 (en) | 1998-05-28 |
JPH10510526A (ja) | 1998-10-13 |
WO1996018413A1 (en) | 1996-06-20 |
FI972484A0 (fi) | 1997-06-12 |
ATE203676T1 (de) | 2001-08-15 |
JP4076230B2 (ja) | 2008-04-16 |
CA2207779A1 (en) | 1996-06-20 |
FI118918B (fi) | 2008-05-15 |
EP0806963A1 (en) | 1997-11-19 |
GB9425060D0 (en) | 1995-02-08 |
AU3988495A (en) | 1996-07-03 |
NO972732D0 (no) | 1997-06-13 |
NO318587B1 (no) | 2005-04-11 |
DE69522012D1 (de) | 2001-09-06 |
EP0806963B1 (en) | 2001-08-01 |
CA2207779C (en) | 2009-10-06 |
FI972484A (fi) | 1997-06-12 |
NO972732L (no) | 1997-06-13 |
DE69522012T2 (de) | 2002-04-25 |
NZ296161A (en) | 2001-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB9425060D0 (en) | Carcinoma treatment | |
MXPA02001726A (es) | Celda de combustible y placa bipolar para utilizarse con la misma. | |
GR3017460T3 (en) | Direct compression cholestyramine tablet and solvent-free coating therefor. | |
EP0617092A3 (en) | Coating diffusing the light, preparation and use. | |
ES8100457A1 (es) | Perfeccionamientos en los dispositivos de borde iluminado | |
HK1052362A1 (en) | Acrylic copolymer partially or fully soluble in water, cured or not and its use | |
ES292314U (es) | Un articulo sanitario | |
MY120408A (en) | Absorbent with half section of gelling material | |
EP0631134A3 (en) | Platform for electrophoresis and plate. | |
TW355847B (en) | A surface treatment steel plate used for battery case, batterycase and battery using the case | |
HRP930344B1 (en) | New retinoides | |
DE59004277D1 (de) | Copolymerisat sowie dessen Verwendung. | |
MX9700298A (es) | Adenovirus que comprende un gen que codifica para una no sintasa. | |
ZA972776B (en) | 4-[(thien-2-yl)methyl]-imidazole analgesics | |
EP0066389A3 (en) | Thermal stabilization of acrylonitrile copolymer fibers | |
JPS57192373A (en) | Halogenopyrimidines, manufacture and use | |
Takeda | Australia-Japan relations in the era of the Anglo-Japanese Alliance, 1896-1911 | |
ZA93733B (en) | New amidine derivatives, the preparation and use thereof. | |
Storm | The contact hypothesis and factors affecting the integration of women in the Canadian military. | |
Bieniecki | THE IMPULSE POWERS SOURCE IN CATHODIC PROTECTION INSTALLATIONS(Polish) | |
Judge | The Manning administration, municipal finance and the Social Credit way of life | |
AU6985194A (en) | Soluble, conductive copolymer, the preparation and use thereof | |
Denniston | “Illuminations” for wind ensemble | |
Sanderson | The insuring intent of the comprehensive general liability policy | |
TW252930B (en) | Dispersion apparatus for polymer solution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
MM | Annulment or lapse due to non-payment of fees |